Each batch of cell therapy is unique because it originates from different starting cells. This inherent variability poses a significant hurdle for process development scientists striving to maintain product quality.
Traditional approaches to achieving consistent outputs in chemistry, manufacturing, and controls (CMC) often struggle to manage the inconsistencies in starting materials, explains Rupa Pike, PhD, global head of strategic alliances at Catalent.
“Cell therapies present unique CMC challenges due to their biological complexity, therapeutic indication, and sensitivity to stress during the manufacturing journey,” says Pike. “The CMC challenges are compounded by the fact cells undergo changes due to selection, genetic modification, expansion, and cryopreservation. These changes make it very difficult to ensure the finished cell therapy product conforms with specified release criteria.”
Pike emphasizes that understanding these obstacles is essential to overcoming them. She advocates for employing all available tools and strategies early in development to maximize the likelihood of creating reliable and scalable processes.
Proactive Risk Mitigation
“Implementing a de-risking strategy early in process development is critical because it allows sponsors to streamline the manufacturing process, address safety and efficacy concerns, and ensure the final drug product meets all the regulatory requirements,” Pike explains.
De-risking measures include applying Quality by Design (QbD) principles to create secure and robust processes. These measures involve performing gap assessments and risk analyses. As a therapy advances through clinical stages, implementing strategies for commercial readiness and ongoing risk management becomes vital.
Emerging bioprocessing technologies are instrumental in helping developers maintain better control over production processes. Digital systems that collect and relay process data exemplify the advancements driving the field forward.
“Innovation in the manufacturing and analytics space is vital for reducing costs and making cell therapies more accessible,” Pike notes. “Data-driven manufacturing is the future for cell therapies as it will empower sponsors and developers to have better control over the manufacturing process, monitor the critical process parameters, and control any drift in the process that may adversely affect the critical quality attributes of the final product.”
Leveraging In-Process Analytics
Real-time cell monitoring technologies, such as the Ovizio imaging system, play a key role in conserving the precious starting materials used in cell therapy. “These technologies are both noninvasive and nondestructive, preserving the valuable materials required for each therapy,” says Pike.
The integration of multiple analytics systems to gather comprehensive data is another critical aspect, Pike explains. Catalent’s proprietary CAR-T platform, UpTempo, exemplifies this approach.
“This platform uses best-in-class GMP-compliant instruments and technologies from multiple vendors to offer our customers an unbiased and data-driven suite of options that fits their specific needs,” says Pike. “The scientific data is complemented by a linked analytical package with a sampling plan that facilitates in-process and robust and rapid release testing, streamlined documentation with templated manufacturing batch records. The goal is to offer a solution that provides efficient manufacturing and a reduction in time and costs.”
Bron: www.genengnews.com